Travere Therapeutics, Inc. (NASDAQ:TVTX) CAO Sandra Calvin Sells 925 Shares

Travere Therapeutics, Inc. (NASDAQ:TVTX) CAO Sandra Calvin sold 925 shares of Travere Therapeutics stock in a transaction on Wednesday, January 22nd. The stock was sold at an average price of $18.94, for a total transaction of $17,519.50. Following the transaction, the chief accounting officer now owns 54,002 shares in the company, valued at $1,022,797.88. This represents a 1.68 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Sandra Calvin also recently made the following trade(s):

• On Thursday, December 26th, Sandra Calvin sold 15,000 shares of Travere Therapeutics stock. The stock was sold at an average price of $17.22, for a total value of $258,300.00.
• On Monday, November 25th, Sandra Calvin sold 12,090 shares of Travere Therapeutics stock. The shares were sold at an average price of $18.30, for a total value of $221,247.00.

Travere Therapeutics Price Performance

NASDAQ TVTX traded up $1.35 during trading on Thursday, hitting $20.81. 2,031,403 shares of the stock traded hands, compared to its average volume of 1,331,242. The company has a quick ratio of 1.68, a current ratio of 1.71 and a debt-to-equity ratio of 24.96. Travere Therapeutics, Inc. has a 12-month low of $5.12 and a 12-month high of $20.89. The firm has a 50-day simple moving average of $18.28 and a 200-day simple moving average of $14.79. The company has a market capitalization of $1.62 billion, a P/E ratio of -4.57 and a beta of 0.70.

Travere Therapeutics (NASDAQ:TVTX) last posted its earnings results on Thursday, October 31st. The company reported ($0.70) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.01. Travere Therapeutics had a negative net margin of 172.75% and a negative return on equity of 537.74%. The firm had revenue of $62.90 million during the quarter, compared to analyst estimates of $60.87 million. Travere Therapeutics’s revenue for the quarter was up 69.6% compared to the same quarter last year. During the same period last year, the firm posted ($1.17) earnings per share. As a group, analysts predict that Travere Therapeutics, Inc. will post -3.92 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on TVTX shares. Bank of America lifted their price objective on Travere Therapeutics from $18.00 to $20.00 and gave the company a “buy” rating in a research report on Wednesday, October 9th. HC Wainwright lifted their price target on shares of Travere Therapeutics from $18.00 to $22.00 and gave the company a “buy” rating in a report on Wednesday, January 15th. Barclays increased their price objective on shares of Travere Therapeutics from $18.00 to $20.00 and gave the stock an “overweight” rating in a research note on Friday, November 1st. Piper Sandler lifted their target price on shares of Travere Therapeutics from $12.00 to $22.00 and gave the company a “neutral” rating in a research note on Thursday, November 14th. Finally, Citigroup cut their price target on Travere Therapeutics from $23.00 to $19.00 and set a “buy” rating for the company in a research note on Friday, September 27th. One analyst has rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $24.00.

Hedge Funds Weigh In On Travere Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Baader Bank Aktiengesellschaft purchased a new stake in shares of Travere Therapeutics during the 4th quarter valued at about $192,000. R Squared Ltd bought a new stake in Travere Therapeutics during the fourth quarter worth approximately $53,000. Diversified Trust Co raised its position in Travere Therapeutics by 27.5% during the fourth quarter. Diversified Trust Co now owns 14,701 shares of the company’s stock valued at $256,000 after purchasing an additional 3,169 shares during the period. Virtu Financial LLC bought a new stake in shares of Travere Therapeutics in the 3rd quarter valued at approximately $301,000. Finally, Geode Capital Management LLC boosted its holdings in shares of Travere Therapeutics by 3.9% in the 3rd quarter. Geode Capital Management LLC now owns 1,731,045 shares of the company’s stock worth $24,222,000 after purchasing an additional 64,744 shares during the period.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.